PLCL2

Across TCGA pan-cancer cohorts, PLCL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLCL2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PLCL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLCL2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where PLCL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.650	0.264	<.001	40	view →
CCRCC	OS	Median	All	1.000	0.657	.005	23	view →
LUAD	OS	Median	All	0.919	0.999	.011	10	view →
GBM	OS	Quartile	All	0.298	0.636	.043	4	view →
LSCC	DFS	Median	II,III,IV	0.561	0.847	.022	4	view →
HNSC	DFS	Tertile	IV	0.815	0.602	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLCL2–PDAC (DFS)

Open the PDAC breakdown →